Lipid Profile Alterations in the Metabolic Syndrome The Latest Biochemical and Physiological Aspect

Dr. Ashfaq ul Hassan; Dr. Shazia Nazir

Authors

Dr. Ashfaq ul Hassan
Dr. Shazia Nazir

Keywords:

apolipoproteins, esterfication, syndrome, circumference, waist, glucocorticoids, lipase

Abstract

Cardiovascular and cerebrovacular complications form a major challenge in the management of the The Metabolic Syndrome. The risks of development are compounded by simultaneous occurrence of Type 2 diabetes mellitus (T2DM), dyslipid emias, hypertension and other medical conditions. The significant increase in morbidity, mortality along with premature death and disabilities resulting from these conditions in both developed and developing is a matter of great concern. The article makes a microanalysis of Biochemical alterations associated with dyslipidemias in cases of metabolic syndrome.

Downloads

How to Cite

Lipid Profile Alterations in the Metabolic Syndrome The Latest Biochemical and Physiological Aspect. (2015). Global Journal of Medical Research, 15(F3), 19-23. https://medicalresearchjournal.org/index.php/GJMR/article/view/954

Download Citation

References

E Shafrir (1993) Animal models of syndrome X. 12, 165-181.

P Lempiainen (1999) Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. 100(2), 123-128.

(2001) Executive Summary of the Thyroid Report of National Cholesterol Education Program (NCEP). 285, 2486-2497.

Pwf Wilson, D' Agostino, R Parise, H Sullivan, L Meigs, J (2005) The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes. 112, 3066-3072.

Delma Nieves, Miriam Cnop, Barbara Retzlaff, Carolyn Walden, John Brunzell, Robert Knopp, Steven Kahn (2003) The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat. 52(1), 172-179.

Robert Ross, Jennifer Freeman, Robert Hudson, Ian Janssen (2002) Abdominal Obesity, Muscle Composition, and Insulin Resistance in Premenopausal Women. 87(11), 5044-5051.

Mark Danese, Paul Ladenson, Curtis Meinert, Neil Powe (2000) Effect of Thyroxine Therapy on Serum Lipoproteins in Patients with Mild Thyroid Failure: A Quantitative Review of the Literature*. 85(9), 2993-3001.

B Wajchenberg (2000) Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome. 21(6), 697-738.

D Nieves, M Cnop, B Retzlaff, C Walden, J Brunzell, R Knopp, S Kahn (2003) The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intraabdominal fat. 52, 172-179.

I Lemieux, A Pascot, C Couillard, B Lamarche, A Tchernof, N Alme Ras, J Bergeron, D Gaudet, G Tremblay, D Prud'homme, A Nadeau, ' Despre, Jp (2000) Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men. 102, 179-184.

Jean-Pierre Després, Alain Golay, Lars Sjöström (2005) Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. 353(20), 2121-2134.

Henry Ginsberg, Li-Shin Huang (2000) The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis. 7(5), 325-331.

Dennis Drayna, Alisha Jarnagin, John Mclean, William Henzel, William Kohr, Christopher Fielding, Richard Lawn (1987) Cloning and sequencing of human cholesteryl ester transfer protein cDNA. 327(6123), 632-634.

Richard Morton (1999) Cholesteryl ester transfer protein and its plasma regulator. 10(4), 321-328.

T Arai, S Yamashita, K Hirano (1994) Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. 14, 1129-1136.

Raija Malmström, Christopher Packard, Timothy Watson, Sirpa Rannikko, Muriel Caslake, Dorothy Bedford, Philip Stewart, Hannele Yki-Järvinen, James Shepherd, Marja-Riitta Taskinen (1997) Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men. 17(7), 1454-1464.

H Ginsberg, N-A Le, I Goldberg, J Gibson, A Rubinstein, P Wang-Iverson, R Norum, W Brown (1986) Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.. 78(5), 1287-1295.

B Lamarchc, A Tchernof, P Mauriege (1998) Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease. 279(24), 1955.

A Chatt, R Brazg, D Tribble (1993) Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. 94, 350-356.

Peter Wilson, Scott Grundy (2003) The Metabolic Syndrome. 108(12), 1422-1424.

P Barter, K Rye (1699) High density lipoproteins and coronary heart disease. 121, 1-12.